Clinical and Microbiologic Outcomes in Patients Receiving Treatment for Mycobacterium abscessus Pulmonary Disease

Jarand, Julie; Levin, Adrah; Zhang, Lening; Huitt, Gwen A.; Mitchell, John D.; Daley, Charles L.

doi:10.1093/cid/ciq237

Cited by 363 publications

(292 citation statements)

References 25 publications

Supporting

Mentioning

274

Contrasting

Unclassified

Order By: Relevance

“…Jarrand and associates reported the results in 69 patients with M. abscessus and PNTM treated either medically or by a combination of medical and surgical treatment and followed for an average of 34 months following treatment. Overall, only 48% of patients achieved a durable conversion to sputum-negative status; 57% of surgical patients and 28% of medical-only patients [100]. Importantly, molecular identification and subspeciation was not performed.…”

Section: Treating Commonly Encountered Speciesmentioning

confidence: 99%

Pulmonary disease caused by nontuberculous mycobacteria

Weiss

Glassroth²

2012

Expert Review of Respiratory Medicine

View full text Add to dashboard Cite

Section: Treating Commonly Encountered Speciesmentioning

confidence: 99%

Pulmonary disease caused by nontuberculous mycobacteria

Weiss

Glassroth²

2012

Expert Review of Respiratory Medicine

View full text Add to dashboard Cite

“…However, these measures have their own limitations and may over-or underestimate disease burden (1,2,9). The chronic and slowly progressive nature of the disease, with required treatment of at least 12-18 months, leads to costly prescription medications and recurring hospital visits as a result of relapse or reinfection (10)(11)(12)(13)(14).…”

mentioning

confidence: 99%

The Burden of Pulmonary Nontuberculous Mycobacterial Disease in the United States

et al. 2015

View full text Add to dashboard Cite

Rationale: State-specific case numbers and costs are critical for quantifying the burden of pulmonary nontuberculous mycobacterial disease in the United States.Objectives: To estimate and project national and state annual cases of nontuberculous mycobacterial disease and associated direct medical costs.Methods: Available direct cost estimates of nontuberculous mycobacterial disease medical encounters were applied to nontuberculous mycobacterial disease prevalence estimates derived from Medicare beneficiary data (2003)(2004)(2005)(2006)(2007). Prevalence was adjusted for International Classification of Diseases, 9th Revision, undercoding and the inclusion of persons younger than 65 years of age. U.S. Census Bureau data identified 2010 and 2014 population counts and 2012 primary insurance-type distribution. Medical costs were reported in constant 2014 dollars. Projected 2014 estimates were adjusted for population growth and assumed a previously published 8% annual growth rate of nontuberculous mycobacterial disease prevalence. Measurements and Main Results:In 2010, we estimated 86,244 national cases, totaling to $815 million, of which 87% were inpatient related ($709 million) and 13% were outpatient related ($106 million). Annual state estimates varied from 48 to 12,544 cases ($503,000-$111 million), with a median of 1,208 cases ($11.5 million). Oceanic coastline states and Gulf States comprised 70% of nontuberculous mycobacterial disease cases but 60% of the U.S. population. Medical encounters among individuals aged 65 years and older ($562 million) were twofold higher than those younger than 65 years of age ($253 million). Of all costs incurred, medications comprised 76% of nontuberculous mycobacterial disease expenditures. Projected 2014 estimates resulted in 181,037 national annual cases ($1.7 billion).Conclusions: For a relatively rare disease, the financial cost of nontuberculous mycobacterial disease is substantial, particularly among older adults. Better data on disease dynamics and more recent prevalence estimates will generate more robust estimates.Keywords: cost analysis; epidemiology; nontuberculous mycobacteria; pulmonary

show abstract

“…Several recent studies regarding treatment outcome in M. abscessus complex lung disease have been reported, with positive results ranging from 25% to 88% (15)(16)(17). The results of these studies may not be generalizable to all patients, because these were retrospective studies utilizing various regimens with different treatment durations, and many patients included in these studies received treatment in combination with surgery.…”

Section: Discussionmentioning

confidence: 99%

Successful treatment of acute respiratory failure in a patient with pulmonary Mycobacterium abscessus infection accompanied by organizing pneumonia

Hong

Kim

2017

J. Thorac. Dis.

View full text Add to dashboard Cite

Organizing pneumonia (OP) is an inflammatory lung disease characterized pathologically by the presence of buds of granulation tissue in the distal air spaces. There are numerous causes of OP including acute respiratory infections such as viral and bacterial infections. However, Mycobacterium abscessus (M. abscessus) has rarely been reported as a causative pathogen of OP. Here, we report a 67-year-old woman with rapidly progressive pulmonary M. abscessus infection who developed OP and acute respiratory failure (ARF).She was treated successfully with a corticosteroid and anti-mycobacterial therapy. Our observations suggest that pulmonary M. abscessus infection should be added to the list of infectious conditions associated with OP.

show abstract

Clinical and Microbiologic Outcomes in Patients Receiving Treatment for Mycobacterium abscessus Pulmonary Disease

Abstract: Patients with M. abscessus pulmonary disease who are treated with multidrug antibiotic therapy and surgery or antibiotic therapy alone had similar clinical outcomes. However, surgical resection, in addition to antibiotics, may offer a prolonged microbiologic response.

Cited by 363 publications

References 25 publications

Pulmonary disease caused by nontuberculous mycobacteria

Pulmonary disease caused by nontuberculous mycobacteria

The Burden of Pulmonary Nontuberculous Mycobacterial Disease in the United States

Successful treatment of acute respiratory failure in a patient with pulmonary Mycobacterium abscessus infection accompanied by organizing pneumonia

Contact Info

Product

Resources

About